Demographics of the study population
| Characteristic . | Apixaban . | Rivaroxaban . | Total . | P . |
|---|---|---|---|---|
| n (%) | 39 (46.4) | 45 (53.6) | 84 (100) | |
| Age, median (IQR) | 77.0 (7.0-81.0) | 73.0 (68.0-84.0) | 75.0 (70.0-83.0) | .52 |
| Female sex, n (%) | 17 (43.4) | 19 (42.2) | 36 (42.9) | 1.0 |
| Body weight, kg, median (IQR) | 75 (67.0-89.0) | 75.0 (65.0-80.0) | 75.0 (66.0-80.0) | .97 |
| Indication for anticoagulation, n (%) | ||||
| SPAF | 34 (87.2) | 29 (64.4) | 63 (75.0) | .01 |
| VTE | 2 (5.1) | 1 (2.2) | 18 (21.4) | |
| SPAF and VTE | 3 (7.7) | 15 (33.3) | 3 (3.6) | |
| History of stroke, n (%) | 11 (28.2) | 10 (22.2) | 21 (25.0) | .62 |
| Concomitant medications, n (%) | ||||
| Antiplatelet agents | 7 (17.9) | 3 (6.7) | 10 (11.9) | .22 |
| NSAID | 2 (5.1) | 0 (0) | 2 (2.4) | .21 |
| Laboratory results at presentation | ||||
| INR | 1.2 (1.1-1.3) | 1.3 (1.1-1.5) | 1.2 (1.1-1.4) | .04 |
| APTT | 35.0 (32.0-39.0) | 41.0 (36.0-49.0) | 38 (34-45) | .01 |
| Creatinine | 77.0 (61.0-83.0) | 79.5 (63.5-99.5) | 77 (62-97) | .39 |
| Bleeding location, n (%) | .95 | |||
| ICH | 29 (74.4) | 30 (66.7) | 59 (70.2) | |
| GI bleeding | 5 (12.8) | 8 (17.8) | 13 (15.5) | |
| Visceral | 2 (5.1) | 3(6.7) | 5 (6.0) | |
| Genitourinary | 2 (5.1) | 2 (4.4) | 4 (4.8) | |
| Musculoskeletal | 1 (2.6) | 2 (4.4) | 3 (3.5) |
| Characteristic . | Apixaban . | Rivaroxaban . | Total . | P . |
|---|---|---|---|---|
| n (%) | 39 (46.4) | 45 (53.6) | 84 (100) | |
| Age, median (IQR) | 77.0 (7.0-81.0) | 73.0 (68.0-84.0) | 75.0 (70.0-83.0) | .52 |
| Female sex, n (%) | 17 (43.4) | 19 (42.2) | 36 (42.9) | 1.0 |
| Body weight, kg, median (IQR) | 75 (67.0-89.0) | 75.0 (65.0-80.0) | 75.0 (66.0-80.0) | .97 |
| Indication for anticoagulation, n (%) | ||||
| SPAF | 34 (87.2) | 29 (64.4) | 63 (75.0) | .01 |
| VTE | 2 (5.1) | 1 (2.2) | 18 (21.4) | |
| SPAF and VTE | 3 (7.7) | 15 (33.3) | 3 (3.6) | |
| History of stroke, n (%) | 11 (28.2) | 10 (22.2) | 21 (25.0) | .62 |
| Concomitant medications, n (%) | ||||
| Antiplatelet agents | 7 (17.9) | 3 (6.7) | 10 (11.9) | .22 |
| NSAID | 2 (5.1) | 0 (0) | 2 (2.4) | .21 |
| Laboratory results at presentation | ||||
| INR | 1.2 (1.1-1.3) | 1.3 (1.1-1.5) | 1.2 (1.1-1.4) | .04 |
| APTT | 35.0 (32.0-39.0) | 41.0 (36.0-49.0) | 38 (34-45) | .01 |
| Creatinine | 77.0 (61.0-83.0) | 79.5 (63.5-99.5) | 77 (62-97) | .39 |
| Bleeding location, n (%) | .95 | |||
| ICH | 29 (74.4) | 30 (66.7) | 59 (70.2) | |
| GI bleeding | 5 (12.8) | 8 (17.8) | 13 (15.5) | |
| Visceral | 2 (5.1) | 3(6.7) | 5 (6.0) | |
| Genitourinary | 2 (5.1) | 2 (4.4) | 4 (4.8) | |
| Musculoskeletal | 1 (2.6) | 2 (4.4) | 3 (3.5) |
NSAID, nonsteroidal anti-inflammatory drug.